New York City-based Mount Sinai Health System published the largest North American study on the Ross procedure, finding it delivers stronger long-term durability and survival than mechanical or biological valve alternatives, it said in a June 23 news release.
The study, published June 23 in Journal of the American College of Cardiology, followed 455 adults who underwent the Ross procedure between 2011 and 2019. The mean patient age was 48, and half the cohort was older than 50.
At 12 years post-surgery, patient survival matched that of the general population. More than 96% of patients avoided cardiac reintervention, and more than 98% showed no significant aortic valve dysfunction. Fewer than 1% required a permanent pacemaker, a lower rate than conventional aortic valve replacement typically produces.
“The Ross procedure is the only aortic valve replacement operation that has consistently been shown to restore life expectancy to that of the general population matched for age and sex,” Ismail El-Hamamsy, MD, PhD, director of aortic surgery at Mount Sinai, said in the release.
The study also found no difference in 12-year outcomes between patients with aortic stenosis and those with aortic regurgitation.
Dr. El-Hamamsy has performed nearly 1,000 Ross procedures and helped launch more than 40 Ross programs across 15 countries.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
